IDEXX Laboratories, Inc. (IDXX)
- Previous Close
489.24 - Open
484.03 - Bid 499.44 x 100
- Ask 500.21 x 100
- Day's Range
484.03 - 500.34 - 52 Week Range
372.50 - 583.39 - Volume
325,844 - Avg. Volume
419,345 - Market Cap (intraday)
41.498B - Beta (5Y Monthly) 1.26
- PE Ratio (TTM)
49.57 - EPS (TTM)
10.08 - Earnings Date May 1, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
604.62
IDEXX Laboratories, Inc. develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy. It also provides point-of-care veterinary diagnostic products, including instruments, consumables, and rapid assay test kits; veterinary reference laboratory diagnostic and consulting services; practice management and diagnostic imaging systems and services for veterinarians; and health monitoring, biological materials testing, and laboratory diagnostic instruments, and services for biomedical research community. In addition, the company offers diagnostic and health-monitoring products for livestock, poultry, and dairy; products that test water for various microbiological contaminants; point-of-care electrolytes and blood gas analyzers; in-clinic chemistry, blood and urine chemistry, hematology, immunoassay, urinalysis, and coagulation analyzers; and SNAP rapid assays test kits. Further, it provides Colilert, Colilert-18, and Colisure tests, which detect the presence of total coliforms and E. coli in water; Enterolert, Pseudalert, Filta-Max and Filta-Max xpress, Legiolert, and Quanti-Tray products; and veterinary software and services for independent veterinary clinics and corporate groups. Additionally, the company offers human medical point-of-care products and laboratory diagnostics services. The company markets its products through marketing, customer service, sales, and technical service groups, as well as through independent distributors and other resellers. IDEXX Laboratories, Inc. was incorporated in 1983 and is headquartered in Westbrook, Maine.
www.idexx.com11,000
Full Time Employees
December 31
Fiscal Year Ends
Sector
Industry
Recent News: IDXX
Performance Overview: IDXX
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: IDXX
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: IDXX
Valuation Measures
Market Cap
40.63B
Enterprise Value
41.25B
Trailing P/E
48.63
Forward P/E
44.84
PEG Ratio (5yr expected)
4.67
Price/Sales (ttm)
11.22
Price/Book (mrq)
27.37
Enterprise Value/Revenue
11.27
Enterprise Value/EBITDA
33.87
Financial Highlights
Profitability and Income Statement
Profit Margin
23.08%
Return on Assets (ttm)
22.83%
Return on Equity (ttm)
80.74%
Revenue (ttm)
3.66B
Net Income Avi to Common (ttm)
845.04M
Diluted EPS (ttm)
10.08
Balance Sheet and Cash Flow
Total Cash (mrq)
453.93M
Total Debt/Equity (mrq)
71.90%
Levered Free Cash Flow (ttm)
693.69M
Research Analysis: IDXX
Company Insights: IDXX
Fair Value
Dividend Score
Hiring Score
Insider Sentiment Score
Research Reports: IDXX
IDXX: Raising target price to $518.00
IDEXX LABORATORIES INC has an Investment Rating of HOLD; a target price of $518.000000; an Industry Subrating of Low; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of Low.
RatingPrice TargetIDXX: Lowering target price to $514.00
IDEXX LABORATORIES INC has an Investment Rating of HOLD; a target price of $514.000000; an Industry Subrating of Low; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of Low.
RatingPrice TargetIDXX: Lowering target price to $546.00
IDEXX LABORATORIES INC has an Investment Rating of HOLD; a target price of $546.000000; an Industry Subrating of Low; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of Low.
RatingPrice TargetIDXX: Lowering target price to $548.00
IDEXX LABORATORIES INC has an Investment Rating of HOLD; a target price of $548.000000; an Industry Subrating of Low; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of Low.
RatingPrice Target